Meanwhile, another two studies treated moderate to severe cutaneous lupus erythematosus (NCT03134222) as well as those afflicted with membranous lupus nephropathy (NCT03285711) with filgotinib or lanraplenib, to investigate the safety and efficacy of the Janus kinase 1 inhibitor filgotinib (FIL) and the spleen tyrosine kinase inhibitor lanraplenib (LANRA) in the treatment of cutaneous lupus erythematosus (CLE). This evidence concerns the gene SYK and cutaneous lupus erythematosus.